RT-RPA-Cas12a-based discrimination of SARS-CoV-2 variants of concern
Zhao,W.,Tang,G.,Zhang,Z.,Tan,W.,Fei,L.,Sun,J.,Li,Y.,Zou,S.,Yang,Y.,Cai,K.,Li,S.,Wang,Z.,Liu,J.,Mao,G.,Ma,Y.,Zhao,G.-P.,Tian,Z.-G.
DOI: https://doi.org/10.1101/2022.05.11.22274884
2022-05-17
MedRxiv
Abstract:Timely and accurate detection of SARS-CoV-2 variants of concern (VOCs) is urgently needed for pandemic surveillance and control. However, current methods are limited by the low sensitivity, long turn-around time or high cost. Here, we report a nucleic acid testing-based method aiming to detect and discriminate SARS-CoV-2 VOCs by combining RT-RPA and CRISPR-Cas12a detecting assays (RRCd). With a detection limit of 10 copies RNA/reaction, RRCd was validated in 204 clinical samples, showing 99% positive predictive agreement and 100% negative predictive agreement, respectively. Critically, using specific crRNAs, representatives of single nucleotide polymorphisms and small deletions in SARS-CoV-2 VOCs including N501Y, T478K and {Delta}H69-V70 were discriminated by RRCd, demonstrating 100% accuracy in clinical samples with Ct <33. The method completes within 65 min and could offer visible results without using any electrical devices, which may facilitate point-of-care testing of SARS-CoV-2 and its variants.